Climb Bio Inc
CLYM5.440USD
+0.790+16.99%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
370.92M시가총액
손실P/E TTM
자세한 내용은 Climb Bio Inc 회사
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc 정보
종목 코드 CLYM
회사 이름Climb Bio Inc
상장일Aug 10, 2021
CEOBrennan (Aoife M)
직원 수17
유형Ordinary Share
회계 연도 종료Aug 10
주소20 William Street
도시WELLESLEY HILLS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02481
전화18668572596
웹사이트https://climbbio.com/
종목 코드 CLYM
상장일Aug 10, 2021
CEOBrennan (Aoife M)
Climb Bio Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
기타
70.41%
주주
주주
비율
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
기타
70.41%
주주 유형
주주
비율
Venture Capital
24.25%
Hedge Fund
9.63%
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
1.15%
Individual Investor
0.81%
Research Firm
0.80%
기타
55.83%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
180
29.55M
43.34%
-39.97M
2025Q3
182
50.11M
95.00%
-5.30M
2025Q2
174
55.41M
95.70%
-2.05M
2025Q1
161
57.46M
90.60%
-8.97M
2024Q4
149
56.10M
86.82%
+979.54K
2024Q3
120
56.83M
81.50%
+4.66M
2024Q2
84
51.93M
31.41%
+31.40M
2024Q1
82
18.86M
80.37%
-3.42M
2023Q4
86
18.86M
80.98%
+125.11K
2023Q3
87
18.73M
82.50%
-1.84K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RA Capital Management, LP
17.90M
26.26%
-13.52M
-43.02%
Dec 12, 2025
Pontifax Venture Capital
5.21M
7.64%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.32M
1.93%
-15.44K
-1.16%
Sep 30, 2025
Affinity Asset Advisors LLC
1.30M
1.91%
-200.00K
-13.33%
Sep 30, 2025
Kynam Capital Management LP
1.03M
1.51%
--
--
Sep 30, 2025
Tang Capital Management, LLC
1.00M
1.47%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
694.98K
1.02%
-134.65K
-16.23%
Sep 30, 2025
Peapod Lane Capital LLC
561.87K
0.82%
+6.20K
+1.12%
Sep 30, 2025
Cantor Fitzgerald, L.P
547.17K
0.8%
-1.96M
-78.14%
Sep 30, 2025
Renaissance Technologies LLC
537.10K
0.79%
+41.60K
+8.40%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
더 보기
ProShares Ultra Nasdaq Biotechnology
비율0.01%
iShares Biotechnology ETF
비율0.01%
Invesco Nasdaq Biotechnology ETF
비율0.01%
iShares Micro-Cap ETF
비율0.01%
Avantis US Small Cap Equity ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
Proshares Ultra Russell 2000
비율0%
ProShares UltraPro Russell2000
비율0%
iShares Neuroscience and Healthcare ETF
비율0%
iShares Russell 2000 Value ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
